Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cabaletta Bio, Inc.

NASDAQ: CABA · Life Sciences · 4 alerts · CIK 1759138

Share price
$1.11Close, Nov 16
Market cap
$239M
Shares outstanding
215.72MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cabaletta Bio, Inc. filings on SEC EDGAR ↗

6:05 AM ET 8-K
Clinical Trial Data

Cabaletta Bio Clinical Trial Data

Cabaletta Bio presented Phase 1/2 clinical data for rese-cel (CABA-201) at the ACR Convergence 2026 meeting, demonstrating durable, immunomodulator-free responses across multiple autoimmune diseases. Key results showed 100% of dermatomyositis patients maintained moderate-to-major improvement scores through one year and 100% of biopsied lupus nephritis patients achieved DORIS remission. The company plans to report topline registrational data in H2 2027 and submit a Biologics License Application in Q1 2028.

“In three different autoimmune diseases where patients are at risk of severe disability, end-organ damage, and increased risk of death despite current therapies, a single weight-based dose of rese-cel delivered immunomodulator-free clinical improvements that were durable through at least one year with a favorable benefit-risk profile.”

David J. Chang, M.D., Chief Medical Officer of Cabaletta

“We believe these emerging data reinforce the potential of rese-cel to deliver an immune reset that leads to durable efficacy with a favorable benefit-risk profile for autoimmune disease patients.”

David J. Chang, M.D., Chief Medical Officer of Cabaletta
8:01 AM ET 8-K
Capital Raise

Cabaletta Bio Capital Raise of $128M

Cabaletta Bio announced the completion of warrant exercises from its June 2025 public offering, resulting in total aggregate gross proceeds of approximately $128.2 million. The warrants, which had an exercise price of $2.50 per share, expired on September 12, 2026, with the vast majority of exercises occurring between July 1, 2026, and the expiration date.

Value
$128M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.